About trabectedin
Antineoplastic alkylating agent
Used for
- Advanced soft-tissue sarcoma after prior chemotherapy
- Ovarian cancer with pegylated liposomal doxorubicin in some regions
Usual adult dose
Soft-tissue sarcoma: 1.5 mg/m² by 24-hour infusion every 3 weeks. Ovarian cancer: 1.1 mg/m² every 3 weeks with pegylated liposomal doxorubicin.
Common side effects
- Nausea, vomiting, constipation, or diarrhea
- Low blood-cell counts and infection risk
- Liver enzyme increases
- Fatigue, appetite loss, or hair loss
Important warnings
- Can cause severe liver injury, muscle breakdown, or heart problems.
- Blood counts and liver and kidney function require monitoring.
- Give through a central venous line; leakage can damage tissue.
- Use only under specialist cancer care.
Pregnancy
May harm an unborn baby. Avoid during pregnancy; effective contraception is recommended during treatment and for 5 months afterward.
Breastfeeding
Breastfeeding is not recommended during treatment and for 3 months after the last dose.
Interactions
- Strong CYP3A inhibitors or inducers can alter trabectedin levels.
- Avoid live vaccines during treatment because immune defenses may be reduced.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.